Engineering of a macromolecular scaffold to develop specific protease inhibitors
- 17 August 2003
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 21 (9) , 1063-1068
- https://doi.org/10.1038/nbt860
Abstract
The specific inhibition of serine proteases, which are crucial switches in many physiologically important processes, is of value both for basic research and for therapeutic applications. Ecotin, a potent macromolecular inhibitor of serine proteases of the S1A family, presents an attractive scaffold to engineer specific protease inhibitors because of its large inhibitor-protease interface. Using synthetic shuffling in combination with a restricted tetranomial diversity, we created ecotin libraries that are mutated at all 20 amino acid residues in the binding interface. The efficacy of these libraries was demonstrated against the serine protease plasma kallikrein (Pkal). Competitive phage display selection yielded a Pkal inhibitor with an apparent dissociation equilibrium constant (K(i)*) of 11 pM, whereas K(i)* values for related proteases (such as Factor Xa (FXa), Factor XIa (FXIa), urokinase-type plasminogen activator (uPA), thrombin, and membrane-type serine protease 1 (MT-SP1)) were four to seven orders of magnitude higher. The adaptability of the scaffold was demonstrated by the isolation of inhibitors to two additional serine proteases, MT-SP1/matriptase and Factor XIIa.Keywords
This publication has 47 references indexed in Scilit:
- Quantitation of Membrane Type Serine Protease 1 (MT-SP1) in Transformed and Normal CellsBiological Chemistry, 2003
- Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarkerBritish Journal of Cancer, 2002
- Human Tissue Kallikreins: A New Enzymatic Cascade Pathway?Biological Chemistry, 2002
- MEROPS: the protease databaseNucleic Acids Research, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Type II Transmembrane Serine ProteasesJournal of Biological Chemistry, 2001
- Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissueProceedings of the National Academy of Sciences, 1999
- Molecular Cloning of cDNA for Matriptase, a Matrix-degrading Serine Protease with Trypsin-like ActivityPublished by Elsevier ,1999
- Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains.Immunogenetics, 1999
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991